Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 8 of 8 results for leuprorelin

  1. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Relugolix for treating hormone-sensitive prostate cancer [ID6187]

    In development [GID-TA11141] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  4. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  5. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced...

    Research recommendation
    Published
    17 October 2016

  6. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887

  7. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  8. Research recommendations

    compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced...